Drug utilization of ezetimibe in rehabilitation centres: registry analysis of factors influencing prescription and effectiveness of treatment

References

• Adult Treatment Panel III. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. J Am Med Assoc 2001;285(19): 2486–97
   Web of Science ®Google Scholar
• Fedder DO, Koro CE, L’Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy – projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105(2):152–6
   Google Scholar
• Wittchen HU, Glaesmer H, Marz W, et al. Cardiovascular risk factors in primary care: methods and baseline prevalence rates – the DETECT program. Curr Med Res Opin 2005;21(4):619–30
   PubMed Web of Science ®Google Scholar
• Keller U. A new class of lipid-lowering drugs: ezetimibe. Heart Drug 2003;3:214–6
   Google Scholar
• Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation 1995;91(8):2274–82
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267–78
   PubMed Web of Science ®Google Scholar
• Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001;357(9262):1063–8
   PubMed Web of Science ®Google Scholar
• Jukema JW, Charbonneau F, Creplet J, et al. The PRevention of Ischemic EveNts by Early Treatment of CErivaStatin (PRINCESS) Study. Presentation (hotline session) at the Annual Meeting of the European Society of Cardiology, Munich, 30 September 2004
   Google Scholar
• Bestehorn KP, Assmann G. Adequate use of statins in Germany? Results from a registry. Presentation at the 11 Jahrestagung 2004 der Gesellschaft für Arzneimittelforschung und Arzneimittelepidemiologie (GAA). 30 September–1 October 2004, Jena, Germany. Available at: http://www.egms.de/en/meetings/gaa2004/04gaa21.shtml [last accessed 30 Jan 2006]
   Google Scholar
• Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women. a reflection of the research evidence? J Clin Epidemiol 2002;55(1):95–101
   PubMed Web of Science ®Google Scholar
• Walley T, Folino-Gallo P, Schwabe U, et al. Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. Eur J Clin Pharmacol 2004;60(7):503–11
   PubMed Web of Science ®Google Scholar
• Deutsche Gesellschaft für Prävention und Rehabilitation von Herz-Kreislauferkrankungen e.V., Koblenz, Germany. URL:www.dgpr.de [last accessed 30 Jan 2006]
   Google Scholar
• Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41–55
   Web of Science ®Google Scholar
• Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(8 Pt 2):757–63
   Google Scholar
• Winkelmayer WC, Kurth T. Propensity scores: help or hype? Nephrol Dial Transplant 2004;19(7):1671–3
   PubMed Web of Science ®Google Scholar
• Euroaspire I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357:995–1001
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227–39
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Schweiger C, Tavazzi L, et al. Epidemiologic study of use of resources in patients with unstable angina: the EARISA registry [On behalf on the EARISA Investigators (Epidemiologia dell’Assorbimento di Risorse nell’Ischemia, Scompenso e Angina)]. Am Heart J 2000;140(2):253–63
   PubMedGoogle Scholar
• Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23(15):1177–89
   Google Scholar
• Hall KH. Reviewing intuitive decision-making and uncertainty: the implications for medical education. Med Educ 2002;36(3):216–24
   PubMed Web of Science ®Google Scholar
• Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150(4):327–33
   PubMed Web of Science ®Google Scholar
• Davidson MH. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther 2003;1(1):11–21
   PubMedGoogle Scholar
• Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hyper-cholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80(5):587–95
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Doherty E, Lumb PJ, et al. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005;21(3):333–8
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44(5):467–94
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Brit Med J 2003;326(7404):1423–30
   Google Scholar
• Kastelein JJ, Sankatsing RR. Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia. Int J Clin Pract 2005;59(12):1464–71
   PubMed Web of Science ®Google Scholar
• Fagan T. Remembering the lessons of basic pharmacology. Arch Intern Med 1994;154:1430–1
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003;326(7404):1427–0
   PubMed Web of Science ®Google Scholar
• Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr Cardiol Rep 2005;7(6):471–9
   PubMedGoogle Scholar
• Kotseva K, Wood D, De Backer G, et al. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet 2001;357(9261):995–1001
   PubMed Web of Science ®Google Scholar
• Ruof J, Klein G, Marz W, et al. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 2002;35(1): 48–53
   PubMed Web of Science ®Google Scholar